Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics Q4 2023 Earnings Report

MoonLake Immunotherapeutics logo
$39.26 -2.64 (-6.30%)
Closing price 04:00 PM Eastern
Extended Trading
$39.31 +0.05 (+0.13%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q4 2023
Time
Before Market Opens
Conference Call Date
Thursday, February 29, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

MoonLake Immunotherapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025

MoonLake Immunotherapeutics Earnings Headlines

This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile

More Earnings Resources from MarketBeat